Press Releases

Date Title and Summary View
Toggle Summary Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics
Peer reviewed article evaluates effect of skin models on in vitro performance of ADAM FREMONT, Calif. , June 20, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic
View HTML
Toggle Summary Zosano Announces Publication of Most Bothersome Symptom Data from the ZOTRIP Pivotal Study in Headache: The Journal of Head and Face Pain
FREMONT, Calif. , May 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied
View HTML
Toggle Summary Zosano Appoints Steven A. Elms to Board of Directors
FREMONT, Calif. , May 22, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update
Completion of follow on offering netting $45.7 million Issuance of new US patent Long-term safety study now has 250 subjects enrolled FREMONT, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company
View HTML
Toggle Summary Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study
250 subjects have enrolled in the Study The Study is set to complete enrollment on May 18th FREMONT, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corp. (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical stage biopharmaceutical company focused on providing rapid systemic administration
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update
FREMONT, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company") a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary Adhesive Dermally-Applied Microarray
View HTML
Toggle Summary Zosano Announces Closing of Public Offering of Common Stock
FREMONT, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the closing of the previously
View HTML
Toggle Summary Zosano Pharma to Host Conference Call to Provide Operational Update
FREMONT, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today
View HTML
Toggle Summary Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to patients using its proprietary ADAM technology, today announced the pricing of an
View HTML
Toggle Summary Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study
103 patients have enrolled in study
View HTML